Your search for bevacizumab returned 150 results

Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease.

The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.

Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.

Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.

Carboplatin plus first-line combination pemetrexed and bevacizumab therapy exhibits efficacy among elderly patients diagnosed with nonsquamous NSCLC, found data presented at ASCO 2013.

Use of injected radioactive beads, with or without bevacizumab, seems to improve survival for patients with metastatic colorectal cancer (mCRC).

For patients with stage 2-3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival.

Adding bevacizumab to chemotherapy for the postsurgical treatment of triple-negative breast cancer does not significantly improve invasive disease-free survival compared with chemotherapy alone.

At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).